HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Metz, L. M. Articles by Meddings, J. B. Search for Related Content PubMed PubMed Citation Articles by Metz, L. M. Articles by Meddings, J. B.

Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis

From the Departments of Clinical Neurosciences (Dr. Metz), Medicine (Drs. Enns and Meddings), and Community Health Sciences (Dr. Hilsden), University of Calgary, and Foothills Hospital (D. Sabuda), Calgary, Alberta, Canada.

Address correspondence and reprint requests to Dr. Luanne Metz, Foothills Hospital, 1403-29 St. N W, Calgary, Alberta, Canada, T2N 2T9.

BACKGROUND: Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks.

METHODS: Gastric mucosal injury, detected by measurement of gastric permeability, was examined after five alternate day doses of IV methylprednisolone (1 g) or oral prednisone (1,250 mg) in 21 patients with MS. A triple sugar test solution was consumed at bedtime, and urine was collected overnight. Urine sugar concentrations were determined by high-pressure liquid chromatography. Gastric permeability was expressed as total mg of sucrose excreted.

RESULTS: Seventeen patients completed the protocol (12 oral, 5 IV). Baseline sucrose excretion was normal in all. Both groups demonstrated an increase in gastric permeability after steroid treatment, but there was no difference between the two groups (95% CI 95 to 91 mg, p = 0.96). After treatment, three (25%) patients in the oral group, and two (40%) patients the IV group, had modestly abnormal gastric permeability (95% CI 34 to 64%, P = 0.6).

CONCLUSIONS: Short-term high-dose oral prednisone is not associated with greater gastric damage, as measured with permeability tests, than IV methylprednisolone. High-dose oral prednisone should be considered a first-line treatment option for MS attacks.

Key words: Corticosteroids—MS—Gastric permeability—Peptic ulcer disease.

This article has been cited by other articles:

				M. Strupp and L. M. Metz The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis Neurology, March 22, 2005; 64(6): 1100 - 1100. [Full Text] [PDF]

				September 28 Highlight and Commentary Neurology, September 28, 2004; 63(6): 945 - 945. [Full Text] [PDF]

				S. A. Morrow, C. A. Stoian, J. Dmitrovic, S. C. Chan, and L. M. Metz The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis Neurology, September 28, 2004; 63(6): 1079 - 1080. [Abstract] [Full Text] [PDF]

				P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]